ADDF Summit
Advancements in Novel Therapeutics and Combination Therapy

Monday, October 28, 2024 | 8am – 5pm
Madrid, Spain
By Invitation Only
Registration Required

The Summit is an invite-only, full-day collaboration of scientists, academics, industry and government professionals, and other pioneers. The symposium seeks to convene and connect those with diverse knowledge in the Alzheimer's field to explore cutting-edge science that will accelerate the development of new treatments—guided by the biology of aging—and advance the field of Alzheimer's disease with innovative approaches to combination therapy and precision medicine.

Register
26
Speakers
19
Speakers
Panel
Discussions
Panel
Discussions
Q&A
Sessions
Q&A
Sessions
Access by
invitation only
Access by
Invitation only

Speakers

Stanley H. Appel, MD
Stanley H. Appel, MD

Director of the Johnson Center for Cellular Therapeutics and Peggy and Gary Edwards Distinguished Endowed Chair in ALS Research at Houston Methodist Research Institute; Professor of Neurology at Weill Cornell Medical College; and Director of the MDA/ALSA ALS Research and Clinical Center

Howard Berman, PhD
Howard Berman, PhD

Founder, Chairman, and Chief Executive Officer of Coya Therapeutics

Joel Braunstein, MD, MBA
Joel Braunstein, MD, MBA

CEO and Co-Founder of C2N Diagnostics

Aaron Burstein, PharmD, FCCP
Aaron Burstein, PharmD, FCCP

Head of Search and Evaluation at Alzheimer’s Drug Discovery Foundation (ADDF)

Jeffrey Cummings, MD, ScD
Jeffrey Cummings, MD, ScD

Joy Chambers-Grundy Professor of Brain Science at the School of Integrated Health Sciences at University of Nevada, Las Vegas (UNLV)

Howard Fillit, MD
Howard Fillit, MD

Co-Founder and Chief Science Officer at the Alzheimer’s Drug Discovery Foundation (ADDF)

Charles Finsterwald, PhD
Charles Finsterwald, PhD

Chief Scientific Officer and Co-Founder of GliaPharm

Georgia Frost, PhD
Georgia Frost, PhD

Senior Associate at the Dementia Discovery Fund (DDF)

Ralph Kern, MD, MHSc
Ralph Kern, MD, MHSc

Chief Medical Officer of Cognito Therapeutics

Miia Kivipelto, MD, PhD
Miia Kivipelto, MD, PhD

Professor of Clinical Geriatrics at Karolinska Institutet’s Center for Alzheimer Research; Senior Geriatrician and Director for Research & Development of Theme Aging at Karolinska University Hospital; and Scientific Founder and Medical and Scientific Director at FINGERS Brain Health Institute (Sweden)

Susan Kohlhaas, PhD
Susan Kohlhaas, PhD

Executive Director of Research and Partnerships at Alzheimer’s Research UK (ARUK)

Eric McDade, DO
Eric McDade, DO

Professor of Neurology at the Washington University School of Medicine in St. Louis; Co-Director of the Dominantly Inherited Alzheimer’s Disease Trials Unit, and Clinical Core Leader of the Dominantly Inherited Alzheimer Network (DIAN) Observational Study

Laura Nisenbaum, PhD, MS
Laura Nisenbaum, PhD, MS

Executive Director of Drug Development at the Alzheimer’s Drug Discovery Foundation (ADDF)

Miranda Orr, PhD
Miranda Orr, PhD

Associate Professor of Internal Medicine in Geriatrics and Gerontology at Wake Forest University School of Medicine; and Research Health Scientist at the Salisbury VA Medical Center

Mark Roithmayr
Mark Roithmayr

CEO of the Alzheimer’s Drug Discovery Foundation (ADDF)

Philip Scheltens, MD, PhD
Philip Scheltens, MD, PhD

Partner and Head of the Dementia Fund at EQT Life Sciences

Suzanne Schindler, MD, PhD
Suzanne Schindler, MD, PhD

Associate Professor of Neurology at Washington University School of Medicine in St. Louis

Charlotte Teunissen, PhD
Charlotte Teunissen, PhD

Professor of Neurochemistry and Chair of the Neurochemistry Lab at Amsterdam UMC

Henrik Zetterberg, MD, PhD
Henrik Zetterberg, MD, PhD

Professor of Neurochemistry at the University of Gothenburg (Sweden) and University College London (UK); and Clinical Chemist at Sahlgrenska University Hospital (Sweden)

Stanley H. Appel, MD
Stanley H. Appel, MD

Director of the Johnson Center for Cellular Therapeutics and Peggy and Gary Edwards Distinguished Endowed Chair in ALS Research at Houston Methodist Research Institute; Professor of Neurology at Weill Cornell Medical College; and Director of the MDA/ALSA ALS Research and Clinical Center

Howard Berman, PhD
Howard Berman, PhD

Founder, Chairman, and Chief Executive Officer of Coya Therapeutics

Joel Braunstein, MD, MBA
Joel Braunstein, MD, MBA

CEO and Co-Founder of C2N Diagnostics

Aaron Burstein, PharmD, FCCP
Aaron Burstein, PharmD, FCCP

Head of Search and Evaluation at Alzheimer’s Drug Discovery Foundation (ADDF)

Jeffrey Cummings, MD, ScD
Jeffrey Cummings, MD, ScD

Joy Chambers-Grundy Professor of Brain Science at the School of Integrated Health Sciences at University of Nevada, Las Vegas (UNLV)

Howard Fillit, MD
Howard Fillit, MD

Co-Founder and Chief Science Officer at the Alzheimer’s Drug Discovery Foundation (ADDF)

Charles Finsterwald, PhD
Charles Finsterwald, PhD

Chief Scientific Officer and Co-Founder of GliaPharm

Georgia Frost, PhD
Georgia Frost, PhD

Senior Associate at the Dementia Discovery Fund (DDF)

Ralph Kern, MD, MHSc
Ralph Kern, MD, MHSc

Chief Medical Officer of Cognito Therapeutics

Miia Kivipelto, MD, PhD
Miia Kivipelto, MD, PhD

Professor of Clinical Geriatrics at Karolinska Institutet’s Center for Alzheimer Research; Senior Geriatrician and Director for Research & Development of Theme Aging at Karolinska University Hospital; and Scientific Founder and Medical and Scientific Director at FINGERS Brain Health Institute (Sweden)

Susan Kohlhaas, PhD
Susan Kohlhaas, PhD

Executive Director of Research and Partnerships at Alzheimer’s Research UK (ARUK)

Eric McDade, DO
Eric McDade, DO

Professor of Neurology at the Washington University School of Medicine in St. Louis; Co-Director of the Dominantly Inherited Alzheimer’s Disease Trials Unit, and Clinical Core Leader of the Dominantly Inherited Alzheimer Network (DIAN) Observational Study

Laura Nisenbaum, PhD, MS
Laura Nisenbaum, PhD, MS

Executive Director of Drug Development at the Alzheimer’s Drug Discovery Foundation (ADDF)

Miranda Orr, PhD
Miranda Orr, PhD

Associate Professor of Internal Medicine in Geriatrics and Gerontology at Wake Forest University School of Medicine; and Research Health Scientist at the Salisbury VA Medical Center

Mark Roithmayr
Mark Roithmayr

CEO of the Alzheimer’s Drug Discovery Foundation (ADDF)

Philip Scheltens, MD, PhD
Philip Scheltens, MD, PhD

Partner and Head of the Dementia Fund at EQT Life Sciences

Suzanne Schindler, MD, PhD
Suzanne Schindler, MD, PhD

Associate Professor of Neurology at Washington University School of Medicine in St. Louis

Charlotte Teunissen, PhD
Charlotte Teunissen, PhD

Professor of Neurochemistry and Chair of the Neurochemistry Lab at Amsterdam UMC

Henrik Zetterberg, MD, PhD
Henrik Zetterberg, MD, PhD

Professor of Neurochemistry at the University of Gothenburg (Sweden) and University College London (UK); and Clinical Chemist at Sahlgrenska University Hospital (Sweden)

Agenda At-A-Glance

Luncheon at 12:15pm.

Morning Session

8:00am - 12:15pm
Session I:
Breakfast, presentations from ADDF-funded investigators, a keynote, and an industry expert-led panel

Afternoon Session

12:15 - 3:50pm
Session II:
Presentations from ADDF-funded investigators, and an industry expert-led panel

At the Marriot Auditorium Hotel & Conference Center
Madrid, Spain

Madrid Marriott Auditorium Hotel & Conference Center

Avenida de Aragon No 400, Madrid, Spain, 28022

This year’s Summit take place at the Marriot Auditorium Hotel & Conference Center.

Register Today